Cargando…

The association between the interval of radioiodine treatment and treatment response, and side effects in patients with lung metastases from differentiated thyroid cancer

OBJECTIVE: Repeat radioiodine (RAI) treatment has been widely implemented for RAI-avid lung metastases and is clinically effective for lung metastatic differentiated thyroid cancer (DTC). We aim to investigate the association between the interval of RAI treatment and short-term response, and the sid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Hongxi, Shi, Lei, Huang, Rui, Liu, Bin, Tian, Rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10264775/ https://www.ncbi.nlm.nih.gov/pubmed/37324277 http://dx.doi.org/10.3389/fendo.2023.1117001

Ejemplares similares

Positive BRAFV600E mutation of primary tumor influences radioiodine avidity but not prognosis of papillary thyroid cancer with lung metastases
por: Huang, Shuhui, et al.
Publicado: (2022)

Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma
por: Du, Wei, et al.
Publicado: (2022)

Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit
por: Wirth, Lori J, et al.
Publicado: (2022)

Radioiodine adjuvant therapy in differentiated thyroid cancer: An update and reconsideration
por: Sun, Yu-qing, et al.
Publicado: (2022)

Alterations in Oral Microbiota of Differentiated Thyroid Carcinoma Patients With Xerostomia After Radioiodine Therapy
por: Lin, Baiqiang, et al.
Publicado: (2022)

Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer
por: Tumino, Dario, et al.
Publicado: (2017)

Distinguishing Patients With Distant Metastatic Differentiated Thyroid Cancer Who Biochemically Benefit From Next Radioiodine Treatment
por: Sa, Ri, et al.
Publicado: (2020)

Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer for Reapplication of I-131 Therapy
por: Hong, Chae Moon, et al.
Publicado: (2017)

A user-friendly nomogram for predicting radioiodine refractory differentiated thyroid cancer
por: Meng, Chao, et al.
Publicado: (2023)

Long-Term Outcomes and Prognoses of Elderly Patients (≥65-Years-Old) With Distant Metastases From Well-Differentiated Thyroid Cancer During Radioiodine Therapy and Follow-Up
por: Qiu, Zhong-Ling, et al.
Publicado: (2021)

Short-Term Side Effects after Radioiodine Treatment in Patients with Differentiated Thyroid Cancer
por: Lu, Liyan, et al.
Publicado: (2016)

Do Molecular Profiles of Primary Versus Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Differ?
por: Gomes-Lima, Cristiane J., et al.
Publicado: (2021)

Association of Radioiodine for Differentiated Thyroid Cancer and Second Breast Cancer in Female Adolescent and Young Adult
por: Zhao, Xianlan, et al.
Publicado: (2022)

Theranostic Options for Radioiodine-Refractory Differentiated Thyroid Carcinoma: Recent Advances, Challenges, and Road Ahead
por: Satapathy, Swayamjeet, et al.
Publicado: (2022)

False-positive radioiodine uptake after radioiodine treatment in differentiated thyroid cancer
por: Barbaro, Daniele, et al.
Publicado: (2023)

Predictive Value of Thyroglobulin Changes for the Curative Effect of Radioiodine Therapy in Patients With Metastatic Differentiated Thyroid Carcinoma
por: Wang, Congcong, et al.
Publicado: (2021)

Delayed Initial Radioiodine Adjuvant Therapy Does Affect Biochemical Response in Intermediate- to High-Risk Differentiated Thyroid Cancer
por: Yu, Feng, et al.
Publicado: (2021)

Long-term prognostic analysis of children and adolescents with differentiated thyroid carcinoma based on therapeutic response to initial radioiodine therapy
por: Wang, Congcong, et al.
Publicado: (2023)

Oxidative stress and radioiodine treatment of differentiated thyroid cancer
por: Buczyńska, Angelika, et al.
Publicado: (2021)

Multimodal approach to the treatment of patients with radioiodine refractory differentiated thyroid cancer and metastases to the central nervous system
por: Alonso‐Gordoa, Teresa
Publicado: (2022)

The potential interaction between medical treatment and radioiodine treatment success: A systematic review
por: Zannat, Riazul, et al.
Publicado: (2023)

Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer
por: Herranz, Urbano Anido
Publicado: (2022)

Prevention of salivary gland dysfunction in patients treated with radioiodine for differentiated thyroid cancer: A systematic review of randomized controlled trials
por: Auttara-atthakorn, Arunrat, et al.
Publicado: (2022)

Therapeutic response and long-term outcome of differentiated thyroid cancer with pulmonary metastases treated by radioiodine therapy
por: Yang, Jing, et al.
Publicado: (2017)

Do radioiodine-avid lymph nodes from differentiated thyroid cancer on the initial posttherapy scan need repeated (131)I therapy?
por: Jiang, Yongji, et al.
Publicado: (2023)

Cost-Effectiveness of Apatinib and Cabozantinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
por: Shi, Bo, et al.
Publicado: (2022)

Breast Cancer After Treatment of Differentiated Thyroid Cancer With Radioiodine in Young Females: What We Know and How to Investigate Open Questions. Review of the Literature and Results of a Multi-Registry Survey
por: Reiners, Christoph, et al.
Publicado: (2020)

Weathering the Storm: Thyroid Storm Precipitated by Radioiodine Contrast in Metastatic Thyroid Carcinoma
por: Basida, Brinda, et al.
Publicado: (2021)

Case Report: Management of an Elderly Patient With Metastatic Radioiodine-Resistant Differentiated Thyroid Cancer in a Rural Community, Remote From Specialist Oncology Services
por: Wybrew, Rachael, et al.
Publicado: (2021)

Radioiodine treatment of differentiated thyroid cancer despite history of ‘iodine allergy’
por: Puchalski, Adam R, et al.
Publicado: (2014)

Sperm DNA fragmentation after radioiodine treatment for differentiated thyroid cancer
por: Esquerré-Lamare, Camille, et al.
Publicado: (2015)

Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study
por: Han, Na, et al.
Publicado: (2023)

Randomized Clinical Trial: Probiotics Alleviated Oral-Gut Microbiota Dysbiosis and Thyroid Hormone Withdrawal-Related Complications in Thyroid Cancer Patients Before Radioiodine Therapy Following Thyroidectomy
por: Lin, Baiqiang, et al.
Publicado: (2022)

GADD45B Transcript Is a Prognostic Marker in Papillary Thyroid Carcinoma Patients Treated With Total Thyroidectomy and Radioiodine Therapy
por: Barros-Filho, Mateus C., et al.
Publicado: (2020)

Brain Metastases From Differentiated Thyroid Carcinoma: A Retrospective Study of 22 Patients
por: Wu, Tong, et al.
Publicado: (2021)

Editorial: New strategies in treatment of differentiated thyroid carcinoma
por: Carrillo, Jose Federico, et al.
Publicado: (2022)

Radioiodine refractoriness score: A multivariable prediction model for postoperative radioiodine‐refractory differentiated thyroid carcinomas
por: Li, Genpeng, et al.
Publicado: (2018)

Gastrointestinal Side Effects of the Radioiodine Therapy for the Patients with Differentiated Thyroid Carcinoma Two Days after Prescription
por: Pashnehsaz, Mehran, et al.
Publicado: (2016)

The reference intervals for thyroid hormones: A four year investigation in Chinese population
por: Xie, Tiancheng, et al.
Publicado: (2023)

Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib
por: Jafri, Sabih, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2fdd5989uvs668djo8ef4lspvm